Select therapeutic use:
Indications for HUMALOG MIX50/50:
≥18yrs: SC inj only. Onset approx ≤15 mins, peak approx 60 mins, duration up to 16hrs.
<18yrs: not established.
During episodes of hypoglycemia.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, cartridges, or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. When mixing insulin lispro with other insulins, draw insulin lispro into syringe first and inject mixture immediately.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Humalog Mix75/25, Humalog vials (10mL)—1; Humalog Mix, Humalog U-100 Kwikpen (prefilled) (3mL)—5; Humalog U-200 Kwikpen (prefilled) (3mL)—2; Humalog cartridges (3mL)—5; HumaPen LUXURA HD (inj device, uses Humalog cartridges)—1